Enterocolitis due to immune checkpoint inhibitors: A systematic review

Gut

Volumn 67, Issue 11, 2018, Pages 2056-2067

  Soularue, Emilie ^a,b   Lepage, Patricia ^b   Colombel, Jean Frederic ^c   Coutzac, Clelia ^d   Faleck, David ^c   Marthey, Lysiane ^a   Collins, Michael ^a,b   Chaput, Nathalie ^b,d   Robert, Caroline ^b,e   Carbonnel, Franck ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d CNRS   (France)

^e Dermatology Unit   (France)

Author keywords

colonic microflora; immunotherapy; inflammatory bowel disease

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; MESALAZINE; METHOTREXATE; NIVOLUMAB; SECUKINUMAB; TOCILIZUMAB; VEDOLIZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ARTICLE; ASEPTIC MENINGITIS; COLITIS; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FAECALIBACTERIUM PRAUSNITZII; FEVER; GASTROINTESTINAL ENDOSCOPY; HEPATITIS; HUMAN; HYPOPHYSITIS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; METASTATIC MELANOMA; NAUSEA AND VOMITING; NEPHRITIS; NONHUMAN; PARENTERAL NUTRITION; PEPTOCLOSTRIDIUM DIFFICILE; PERICARDITIS; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UVEITIS; X-RAY COMPUTED TOMOGRAPHY; CELL CYCLE CHECKPOINT; CHEMICALLY INDUCED; DRUG EFFECT; ENDOSCOPY; PROCEDURES; RISK FACTOR;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CELL CYCLE CHECKPOINTS; ENDOSCOPY; ENTEROCOLITIS; GASTROINTESTINAL MICROBIOME; HUMANS; RISK FACTORS;

EID: 85052707584     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2018-316948     Document Type: Article

References (135)

1. Bates SE. Refining Immunotherapy Approvals. Clin Cancer Res 2017;23:4948-9.
2. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapyrefractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17:1374-85.
3. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet 2017;389:2492-502.
4. Kang Y-K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2017;390:2461-71.
5. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal Junction cancer. JAMA Oncol 2018;4:e180013.
6. D'Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018;19:416-26.
7. Khoja L, Day D, Wei-Wu Chen T, et al. Tumour-and class-specific patterns of immunerelated adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology 2017;28:2377-85.
8. Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805.
9. Tandon P, Bourassa-Blanchette S, Bishay K, et al. The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis. J Immunother 2018;41:101-8.
10. Betof AS, Nipp RD, Giobbie-Hurder A, et al. Impact of age on outcomes with immunotherapy for patients with melanoma. Oncologist 2017;22:963-71.
11. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017;18:611-22.
12. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016;2:234-40.
13. Kähler KC, Eigentler TK, Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunology, Immunotherapy 2018;67:825-34.
14. Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017;75:24-32.
15. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368-76.
16. Bostwick AD, Salama AK, Hanks BA. Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 2015;3:19.
17. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.
18. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-?1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 2015;3:39.
19. Schindler K, Harmankaya K, Kuk D, et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. J Clin Oncol 2014;32:9096.
20. Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017;152:362-73.
21. Gambichler T, Brown V, Steuke A-K, et al. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. J Dermatol Venereol 2017
22. Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One 2016;11:e0160221.
23. Gupta A, De Felice KM, Loftus EV, et al. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 2015;42:406-17
24. Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278.
25. Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with Anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. Journal of Crohn's and Colitis 2016;10:395-401.
26. Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, Endoscopic, and Histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 2016;14:836-42.
27. O'Connor A, Marples M, Mulatero C, et al. Ipilimumab-induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol 2016;9:457-62.
28. De Felice KM, Gupta A, Rakshit S, et al. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res 2015;25:321-7.
29. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-Lymphocyte-associated antigen 4. Journal of Clinical Oncology 2006;24:2283-9.
30. Lord JD, Hackman RC, Moklebust A, et al. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2010;55:1396-405.
31. Weber JS, Dummer R, Pril de V, et al. Patterns of onset and resolution of immunerelated adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013;119:1675-82.
32. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13:473-86.
33. Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients With melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 2015;33:3193-8.
34. Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy. N Engl J Med Overseas Ed 2016;375:1845-55.
35. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med Overseas Ed 2010;363:711-23.
36. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 2015;7:1213-27.
37. Bhatia S, Huber BR, Upton MP, et al. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009;32:203-5.
38. Gaudy-Marqueste C, Monestier S, Franques J, et al. A severe case of ipilimumabinduced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 2013;36:77-8.
39. Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab-associated colitis: CT findings. AJR Am J Roentgenol 2013;200:W468-W474.
40. Garcia-Neuer M, Marmarelis ME, Jangi SR, et al. Diagnostic comparison of ct scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res 2017;5:286-91.
41. Jain A, Lipson EJ, Sharfman WH, et al. Colonic ulcerations may predict steroidrefractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol 2017;23:2023-8.
42. Shah R, Witt D, Asif T, et al. Ipilimumab as a cause of severe pan-colitis and colonic perforation. Cureus 2017;9:e1182.
43. Messmer M, Upreti S, Tarabishy Y, et al. Ipilimumab-induced enteritis without colitis: A new challenge. Case Rep Oncol 2016;9:705-13.
44. García-Varona A, Odze RD, Makrauer F. Lymphocytic colitis secondary to ipilimumab treatment. Inflamm Bowel Dis 2013;19:E15-E16.
45. Coutzac C, Adam J, Soularue E, et al. Colon immune-related adverse events: Anti-CTLA-4 and Anti-PD-1 Blockade induce distinct immunopathological entities. J Crohns Colitis 2017;11:1238-46.
46. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebocontrolled, phase II Study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or iv melanoma. Clinical Cancer Research 2009;15:5591-8.
47. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv119-iv142.
48. O'Day S, Weber JS, Wolchok JD, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. Journal of Clinical Oncology 2011;29:8554.
49. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40.
50. Hillock NT, Heard S, Kichenadasse G, et al. Infliximab for ipilimumab-induced colitis: A series of 13 patients. Asia Pac J Clin Oncol 2017;13:e284-e290.
51. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunology, Immunotherapy 2017;66:581-92
52. Lankes K, Hundorfean G, Harrer T, et al. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. Oncoimmunology 2016;5:e1128611.
53. Franklin C, Rooms I, Fiedler M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer 2017;86:248-56.
54. Mitchell KA, Kluger H, Sznol M, et al. Ipilimumab-induced Perforating Colitis. J Clin Gastroenterol 2013;47:781-5.
55. De Malet A, Soularue E, Collins M, et al. (JFHOD 2018)|. https://www. snfge. org/ content/ evolution-long-terme-des-gastrites-et-enterocolites-induites-par-lesinhibiteurs-d.e.
56. Akel R, Anouti B, Tfayli A. Late-onset inflammatory bowel disease-like syndrome after ipilimumab therapy: A case report. Case Rep Oncol 2017;10:456-61.
57. Wei W, Luo Z. Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. Medicine 2017;96:96.
58. Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785-92.
59. Collins M, Michot JM, Danlos FX, et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol 2017;28:2860-5.
60. Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. Histopathology 2017;70:558-67.
61. Yasuda Y, Urata Y, Tohnai R, et al. Immune-related colitis induced by the long-term use of nivolumab in a patient with non-small cell lung cancer. Intern Med Tokyo Jpn 2017.
62. Chen JH, Pezhouh MK, Lauwers GY, et al. Histopathologic features of colitis due to immunotherapy with anti-pd-1 antibodies. Am J Surg Pathol 2017;41:643-54.
63. Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209.
64. Abe K, Nakamura N, Isono A, et al. Inflammatory bowel disease in an elderly woman after nivolumab administration. Am J Gastroenterol 2017;112:1636.
65. Baroudjian B, Lourenco N, Pagès C, et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res 2016;26:308-11.
66. Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Archiv 2018;472:125-33.
67. Bavi P, Butler M, Serra S, et al. Immune modulator-induced changes in the gastrointestinal tract. Histopathology 2017;71:494-6.
68. Bamias G, Delladetsima I, Perdiki M, et al. Immunological characteristics of colitis associated with Anti-CTLA-4 antibody therapy. Cancer Invest 2017;35:443-55.
69. Arriola E, Wheater M, Lopez MA, et al. Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. Oncoimmunology 2016;5:5.
70. Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J 2017:4.
71. Weber JS, Postow M, Lao CD, et al. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 2016;21:1230-40.
72. Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol 2017;15:e80-e81.
73. Kubo K, Kato M, Mabe K. Nivolumab-associated colitis mimicking ulcerative colitis. Clin Gastroenterol Hepatol 2017;15:A35-A36.
74. Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2017;1:1078155217745144.
75. Bertha M, Bellaguara E, Kuzel T, et al. Checkpoint inhibitor-induced colitis: A new type of inflammatory bowel disease? ACG Case Rep J 2017:4.
76. Esfahani K, Miller WH. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. N Engl J Med Overseas Ed 2017;376:1989-91.
77. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med Overseas Ed 2015;373:23-34.
78. D'Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis. J Clin Oncol 2017;35:226-35.
79. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med Overseas Ed 2017;377:1345-56.
80. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med Overseas Ed 2015;372:2006-17.
81. Hodi FS, Chesney J, Pavlick AC, et al. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol 2016;17:1558-68.
82. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41.
83. Hassel JC, Heinzerling L, Aberle J, et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 2017;57:36-49.
84. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017;28:1368-79.
85. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22:886-94.
86. Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 2011;28:1140-4.
87. Arriola E, Wheater M, Karydis I, et al. Infliximab for IPILIMUMAB-Related colitisletter. Clin Cancer Res 2015;21:5642-3.
88. Aya F, Fernández-Martínez A, Gaba L, et al. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab. Immunotherapy 2016;8:687-92.
89. Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018;29:250-5.
90. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic ?-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
91. Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T Cell-mediated immunotherapy. Cancer Discov 2016;6:202-16.
92. Ugurel S, Schrama D, Keller G, et al. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother 2008;57:685-91.
93. Breunis WB, Tarazona-Santos E, Chen R, et al. Influence of cytotoxic T lymphocyteassociated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008;31:586-90.
94. Nomizo T, Ozasa H, Tsuji T, et al. Clinical impact of single nucleotide polymorphism in pd-l1 on response to nivolumab for advanced non-small-cell lung cancer patients. Sci Rep 2017;7:7.
95. Bins S, Basak EA, el Bouazzaoui S, et al. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. Br J Cancer 2018;118:1296-301.
96. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079-84.
97. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084-9.
98. Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016:7.
99. Frankel AE, Coughlin LA, Kim J, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 2017;19:848-55.
100. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-7.
101. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97-103.
102. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104-8.
103. Wei SC, Levine JH, Cogdill AP, et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell 2017;170:1120-33.
104. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010;16:2861-71.
105. Wang F, Yin Q, Chen L, et al. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A 2018;115:157-61.
106. Coquerelle C, Oldenhove G, Acolty V, et al. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009;58:1363-73.
107. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol 2016;13:13-27.
108. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010;28:573-621.
109. Kaplan GG, Ng SC, Sc N. Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 2017;152:313-21.
110. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012;143:62-9.
111. Freeman GJ, Gribben JG, Boussiotis VA, et al. Cloning of B7-2: a CTLA-4 counterreceptor that costimulates human T cell proliferation. Science 1993;262:909-11.
112. Azuma M, Ito D, Yagita H, et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-9.
113. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011;332:600-3.
114. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65.
115. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999;77:1-10.
116. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006;212:131-48.
117. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
118. Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27:235-43.
119. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.
120. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
121. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
122. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
123. Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013;14:1212-8.
124. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10:1185-92.
125. Nurieva R, Thomas S, Nguyen T, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. Embo J 2006;25:2623-33.
126. Patsoukis N, Bardhan K, Chatterjee P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 2015;6:6692.
127. Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal 2012;5:ra46.
128. Patsoukis N, Li L, Sari D, et al. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol 2013;33:3091-8.
129. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1. Nat Immunol 2001;2:261-8.
130. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010;38:D355-D360.
131. Abubucker S, Segata N, Goll J, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput Biol 2012;8:e1002358.
132. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971-6.
133. Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006;177:4376-83.
134. Barnes MJ, Griseri T, Johnson AM, et al. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol 2013;6:324-34.
135. Zeissig S, Petersen BS, Tomczak M, et al. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4. Gut 2015;64:1889-97.